These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 7444073)

  • 1. Reflections on cancer treatment and the federal agency regulations.
    Saenger EL; Kereiakes JG
    Radiology; 1980 Dec; 137(3):865-6. PubMed ID: 7444073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic 131I in outpatients: a simplified method conforming to the Code of Federal Regulations, title 10, part 35.75.
    Coover LR; Silberstein EB; Kuhn PJ; Graves MW
    J Nucl Med; 2000 Nov; 41(11):1868-75. PubMed ID: 11079497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NRC absorbed dose reconstruction for family member of 131I therapy patient: case study and commentary.
    Marcus CS; Siegel JA
    J Nucl Med; 2004 Apr; 45(4):13N-6N, 37N. PubMed ID: 15073236
    [No Abstract]   [Full Text] [Related]  

  • 4. Applying Nuclear Regulatory Commission guidelines to the release of patients treated with sodium iodine-131.
    Tuttle WK; Brown PH
    J Nucl Med Technol; 2000 Dec; 28(4):275-9. PubMed ID: 11142331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Licensee over-reliance on conservatisms in NRC guidance regarding the release of patients treated with 131I.
    Siegel JA; Marcus CS; Stabin MG
    Health Phys; 2007 Dec; 93(6):667-77. PubMed ID: 17993847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : practice recommendations of the American Thyroid Association.
    ; Sisson JC; Freitas J; McDougall IR; Dauer LT; Hurley JR; Brierley JD; Edinboro CH; Rosenthal D; Thomas MJ; Wexler JA; Asamoah E; Avram AM; Milas M; Greenlee C
    Thyroid; 2011 Apr; 21(4):335-46. PubMed ID: 21417738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The AEC/NRC 30 mCi rule: regulatory origins and clinical consequences for 131I remnant ablative doses.
    Siegel JA; Silberstein EB
    Thyroid; 2014 Nov; 24(11):1625-35. PubMed ID: 25045970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of thyroid carcinoma: emphasis on high-dose 131I outpatient therapy.
    Parthasarathy KL; Crawford ES
    J Nucl Med Technol; 2002 Dec; 30(4):165-71; quiz 172-3. PubMed ID: 12446749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outpatient therapeutic 131I for thyroid cancer.
    Panzegrau B; Gordon L; Goudy GH
    J Nucl Med Technol; 2005 Mar; 33(1):28-30. PubMed ID: 15731017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation safety precautions in the management of the hospitalized (131)I therapy patient.
    Thompson MA
    J Nucl Med Technol; 2001 Jun; 29(2):61-6; test 74-5. PubMed ID: 11376097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hospital discharge of patients with thyroid carcinoma treated with 131I.
    Venencia CD; Germanier AG; Bustos SR; Giovannini AA; Wyse EP
    J Nucl Med; 2002 Jan; 43(1):61-5. PubMed ID: 11801704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation safety protocol for high dose 131I therapy of thyroid carcinoma in patients on hemodialysis for chronic renal failure.
    Modarresifar H; Almodovar S; Bass WB; Ojha B
    Health Phys; 2007 Feb; 92(2 Suppl):S45-9. PubMed ID: 17228187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between external exposure and activity in patients undergoing 131I thyroid cancer therapy.
    Barquero R; Basurto F; Vega-Carrillo HR; Iñiguez MP; Ferrer N; Esteban R
    Health Phys; 2008 Aug; 95(2):227-33. PubMed ID: 18617804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure of low doses of 131I to ablate residual thyroid tissue following surgery for thyroid cancer.
    Kuni CC; Klingensmith WC
    Radiology; 1980 Dec; 137(3):773-4. PubMed ID: 7444061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of methods for assessing patient body burden following 131I therapy for thyroid cancer.
    Thomas SR; Maxon HR; Fritz KM; Kereiakes JG; Connell WD
    Radiology; 1980 Dec; 137(3):839-42. PubMed ID: 7444070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. License terms for medical use licenses--NRC. Final rule.
    Fed Regist; 1998 Jun; 63(111):31604-7. PubMed ID: 10180132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 131I ablation treatment in young females after the Chernobyl accident.
    Travis CC; Stabin MG
    J Nucl Med; 2006 Oct; 47(10):1723-7. PubMed ID: 17015910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of 124I PET/CT imaging to predict absorbed doses in patients affected by metastatic thyroid cancer and treated with 131I.
    Pettinato C; Monari F; Nanni C; Allegri V; Marcatili S; Civollani S; Cima S; Spezi E; Mazzarotto R; Fanti S
    Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):509-14. PubMed ID: 23358403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cumulative doses of adjunct 131I treatment depend on location of residual thyroid tissue after total thyroidectomy in differentiated thyroid cancer.
    Saint-Vil D; Emran MA; Lambert R; Alos N; Turpin S; Huot C
    J Pediatr Surg; 2007 May; 42(5):853-6. PubMed ID: 17502198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation protection issues associated with nuclear medicine out-patients.
    Thomson WH; Harding LK
    Nucl Med Commun; 1995 Nov; 16(11):879-92. PubMed ID: 8587752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.